<?xml version="1.0" encoding="UTF-8"?>
<p id="para0002">At the time of this writing, COVID-19 pandemic continues unabated in many parts of the globe. Although most people infected with SARS-CoV2 experience mild to moderate respiratory symptoms and recover with supportive care, certain hosts (even including younger, previously healthy ones) are more likely to develop a precipitous clinical decline. Current data support that hyperimmune host reactions triggered by the virus are at least partially responsible for these poor outcomes 
 <xref rid="bib0002" ref-type="bibr">[2]</xref>. Early identification and intervention in these high-risk patients may provide a means to disease amelioration and potentially expedited recovery, although to date no pharmacological therapy has been identified.
</p>
